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Candida peritonitis is a crucial disease, however the optimal antifungal therapy regimen has not been 
clearly defined. Peritoneal fibrosis (PF) can be caused by abdominal surgery, intra-abdominal infection, 
and malignant diseases, and is also widely recognized as a crucial complication of long-term peritoneal 
dialysis. However, the influence of PF on Candida peritonitis prognosis remains unknown. Here, we 
evaluated the severity of Candida peritonitis within the context of PF and the efficacy of micafungin 
using mice. A PF mouse model was generated by intraperitoneally administering chlorhexidine 
gluconate. Candida peritonitis, induced by intraperitoneal inoculation of Candida albicans, was treated 
with a 7-day consecutive subcutaneous administration of micafungin. Candida infection caused a higher 
mortality rate in the PF mice compared with the control mice on day 7. Proliferative Candida invasion 
into the peritoneum and intra-abdominal organs was confirmed pathologically only in the PF mice. 
However, all mice in both groups treated with micafungin survived until day 20. Micafungin treatment 
tends to suppress inflammatory cytokines in the plasma 12 h after infection in both groups. Our results 
suggest that PF enhances early mortality in Candida peritonitis. Prompt initiation and sufficient doses 
of micafungin had good efficacy for Candida peritonitis, irrespective of the underlying PF.
Peritoneal dialysis (PD) is an effective treatment for end-stage renal disease1–3; however, several complications 
occur in patients undergoing PD. Peritoneal fibrosis (PF) is a pathological change occurring in the peritoneal 
membrane induced by long-term PD, which impairs the efficiency of dialysis and results in withdrawal from PD4. 
Infective peritonitis is also a common problem occurring in PD patients, which can be crucial. Bacteria, such as 
staphylococcal species, are common causative organisms of peritonitis5,6, but fungi, especially Candida species, 
are also important pathogens, which lead to high mortality rate of up to ≥25%7–11. Candida albicans is the most 
common species detected in >50% of cases10,11. Nevertheless, the optimal antifungal therapy regimen has not 
been clearly defined.
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For fungal peritonitis, the International Society for Peritoneal Dialysis (ISPD) guideline updated in 2016, 
advocates for immediate catheter removal and antifungal therapy; however, the appropriate antifungal agent, for 
the initial therapy, has not been clearly defined12. Intra-abdominal candidiasis, such as peritonitis or abscesses, is 
considered much more common than recognized13. The causes of intra-abdominal candidiasis are not only from 
PD but also from intra-abdominal surgery, anastomotic leakage, and pancreatitis14. The Infectious Disease Society 
of America (IDSA) guideline on the management of candidiasis, updated in 2016, recommends echinocandin as 
an initial therapy for intra-abdominal candidiasis irrespective of the presence or absence of PF14. Micafungin is 
one of the antifungal agents belonging to the echinocandins class; and has been shown to have good antifungal 
activity even against non-albicans Candida species15,16. Non-albicans Candida species have recently increased as 
causative organisms in candidiasis patients17–19. However, C. albicans remains the predominant species causing 
Candida peritonitis. Furthermore, echinocandins are easy to use, with minimal adverse effects20–22. For these 
reasons, the clinical use of micafungin has recently increased.
PF and Candida peritonitis, two complications in PD patients, have been evaluated thus far; and severe or 
prolonged infective peritonitis is known to induce PF23,24. Yet, the influence of PF on peritoneal infection has 
not been adequately investigated. Therefore, evaluation of the efficacy of antifungal therapy for Candida peri-
tonitis developed in the context of PF is essential among PD patients who suffer from Candida peritonitis. 
Furthermore, it could be useful for treating patients with Candida peritonitis in the context of abdominal surgery, 
intra-abdominal infection, and malignant diseases who may develop PF25–27. In this study, we evaluated whether 
PF has any influence on the prognosis of Candida peritonitis and on the efficacy of micafungin treatment, using 
PF mouse models.
Results
Evaluation of PF. PF was experimentally induced in mice by repeated intraperitoneal administration of 
chlorhexidine gluconate (CG) (Fig. 1A). In the control group, the mice peritoneal tissue consisted of a peri-
toneal mesothelial monolayer, with sparse connective tissues below the layer. Compared to the control group, 
the peritoneal tissues of the mice in the PF group showed significant thickening of the submesothelial compact 
zone (p < 0.0001, unpaired t test), and the presence of numerous inflammatory cells and fibroblasts as previously 
reported4 (Fig. 1B).
Evaluation of survival. We evaluated survival curves of the control and PF mice with or without micafungin 
treatment (Fig. 2A). When untreated with micafungin, the PF mice showed a higher mortality rate than the con-
trol mice on day 7 (p = 0.013, Kaplan-Meier log-rank test) but there was no statistically significant difference in 
survival rate on day 20 between these two groups (p = 0.29, Kaplan-Meier log-rank test). In both PF and control 
groups, all mice treated with micafungin survived until the end of the experiment (day 20).
Evaluation of the fungal burden in the liver, spleen, kidneys, and blood. The fungal burden in the 
liver, spleen, kidneys, and blood were evaluated at 6 h, 12 h, and 7 days after the infection (Fig. 2B). The fungal 
burden of the PF mice without micafungin treatment on day 7 was not assessed because majority of this group 
died as shown in Fig. 2A. At early timepoints, micafungin treatment significantly reduced fungal burden in all the 
organs examined in both control and PF mice at 12 h, but only in the control mice at 6 h. Blood stream infection 
(positive blood culture) was detected in some PF mice at 6 and 12 h but successfully treated with micafungin. 
Micafungin treatment also reduced fungal burden of spleen and kidneys in control mice on day 7 compared with 
no-treatment mice. In both control and PF groups with micafungin treatment, fungal burden was significantly 
decreased in all the organs on day 7 compared with the data at 12 h (except for spleen of PF group).
Histopathological evaluation of Candida cells in the peritoneum and organs. Grocott staining 
of the peritoneum showed abscess formation in a markedly thickened submesothelial zone with the presence 
of many Candida cells in most PF mice without micafungin treatment at 12 h after the infection (Fig. 3A,B). 
hematoxylin and eosin (H & E) staining confirms numerous inflammatory cells in the same sections (Fig. 3C). 
However, Candida proliferation was hardly observed in PF group with micafungin treatment (Fig. 3D). Candida 
cells were also hardly confirmed in both control groups with or without micafungin treatment probably due to 
the early timepoint of evaluation.
Grocott staining of the liver (Fig. 3E,F) and spleen (Fig. 3H,I) showed proliferative Candida infiltration into 
the subcapsular structure inside the organ in most PF mice without micafungin treatment at 12 h after the infec-
tion. H & E staining confirms numerous inflammatory cells in both organs (Fig. 3G,J). Adhesion of Candida 
cells to the surface of the organ was observed in some mice in both control groups (with or without micafungin 
treatment) and PF group (with micafungin treatment), although infiltration inside the organ was not detected in 
any mice in these groups. No Candida cell was detected in the kidneys in all the groups (photographs not shown).
Evaluation of the cytokines in the blood. We quantified the plasma cytokine concentrations to evaluate 
an inflammatory response in the Candida peritonitis mouse models. At 12 h after the infection, interferon-gamma, 
interleukin-10, interleukin-17A, interleukin-1 beta, interleukin-6, and tumor necrosis factor alpha (TNF-α) 
tended to be suppressed with micafungin treatment in both PF and control mouse models (Fig. 4A). We also 
used lipopolysaccharide (LPS) instead of C. albicans to evaluate if micafungin exerts an anti-inflammatory effect 
irrespective of the Candida infection. The plasma concentration of TNF-α was increased by intraperitoneal LPS 
injection but not suppressed with micafungin administration in both PF and control groups (Fig. 4B).
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Discussion
Long-term PD causes histopathological changes, such as PF, in the peritoneum24, associated with mesothelial loss, 
severe thickening of the submesothelial compact zone, and vascular alterations3. Severe or prolonged infective 
peritonitis also leads to PF, eventually leading to membrane23,24 and organ failures28. However, the influence of PF 
in the prognosis of peritonitis remains to be evaluated. In the present study, we evaluated the severity of C. albi-
cans peritonitis in the context of PF using mouse models induced by CG exposure. Although, some differences 
exist between CG-induced PF and human PF with PD therapy, most of the pathological changes between them 
are similar. These include, expression of collagen and alpha-smooth muscle actin, macrophage infiltration, and 
neovascularization in the peritoneum29. Therefore, CG mouse models have been used to investigate the pathogen-
esis and therapy of PF4,30–32. In our study, the presence of PF enhanced early mortality in mice with Candida peri-
tonitis during the first 7 days. In a histopathological evaluation, we hereby showed the proliferation of Candida 
cells, invading into the liver and spleen tissues, only in the PF group without micafungin treatment; whereas, with 
micafungin treatment, it was inhibited. Interestingly, no infiltration was found in all the control mice regardless of 
micafungin treatment. That no Candida cell invasion was detected histopathologically in the kidneys might have 
resulted from the location of these organs in the retroperitoneal space, which is separated from the intraperitoneal 
space. In addition, the absolute number of Candida cells in kidneys were approximately 100 times less than those 
in other two organs. The proliferation of Candida cells in the peritoneum was also detected only in the PF mice 
without micafungin treatment, histopathologically. Considering all these findings, the damage to the peritoneal 
membrane and a remarkable intraperitoneal Candida proliferation followed by candidemia, which was confirmed 
Figure 1. Schematic study design of the present study and histopathological evaluation of PF. (A) Mice received 
9 intraperitoneal injections of 0.1% CG or a vehicle (15% ethanol) at a dose of 0.2 mL/mouse in 3 weeks, 
followed by one injection with 1 mL of the C. albicans cell suspension (5.0 × 107 CFU/mouse). Micafungin 
dissolved in sterile saline was subcutaneously administered at a dose of 5 mg/kg daily for 7 days, beginning 2 h 
after the infection. (B) Masson’s trichrome staining of peritoneal tissues at 100-fold magnification. Bars indicate 
the thickness of the submesothelial compact zone. In the control group, the monolayer of mesothelial cells 
covered the entire surface of the peritoneum. In the PF group, the submesothelial compact zone was markedly 
thickened. Bar graph shows the thickness of the submesothelial compact zones in the control and PF groups. 
The PF group showed significant thickening compared to the control group. An asterisk indicates p < 0.0001 
(unpaired t test). Both control and PF groups in this assay were not inoculated with Candida. These results 
were confirmed on two separate occasions and representative data are shown. PF, peritoneal fibrosis; CG, 
chlorhexidine gluconate; SS, sterile saline; i.p., intraperitoneal injection; and s.c., subcutaneous injection.
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Figure 2. Evaluation of survival assay and the fungal burden in the liver, spleen, and kidneys. (A) Survival 
curves were plotted for the following four groups (n = 8 for each group); control without micafungin treatment 
(open circles); PF without micafungin treatment (open triangles); control with micafungin treatment (filled 
circles); and PF with micafungin treatment (filled triangles). Without micafungin treatment, the PF mice had 
significantly higher mortality than the control mice on day 7 (p = 0.013, Kaplan-Meier log-rank test), although 
both groups showed no significant difference on day 20 (p = 0.29). All the PF and control mice treated with 
micafungin survived until the end of the experiment (day 20) (vs. untreated group, p < 0.01 each). Similar 
results were obtained in three different experiments and representative data are shown. (B) Fungal burden 
in the liver, spleen, bilateral kidneys, and blood was evaluated 6 h, 12 h, and 7 days after the infection (n = 10 
for each group). In the control mice, fungal burden in the three target organs at 6 and 12 h, and that in spleen 
and kidneys on day 7 was significantly reduced by micafungin treatment. In the PF mice, there was significant 
difference in the fungal burden between micafungin-treated and -untreated groups at 12 h, but not at 6 h. Fungal 
burdens of all the three organs in the control mice and two organs (liver and kidneys) in the PF mice were 
significantly reduced by micafungin treatment on day 7 compared with the results at 12 h. Asterisks indicate 
p < 0.0083 (Mann-Whitney U test adjusted with Bonferroni correction). PF, peritoneal fibrosis.
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by the significant increase of fungal burden in the bloodstream at 12 h, are thought to have caused the early high 
mortality phase in the PF group.
In our study, we confirmed all mice in both PF and control groups were successfully treated with early initi-
ation of micafungin 2 h after C. albicans inoculation based on the results of survival, fungal burden, and histo-
pathological findings. Drug penetration into the site of infection to achieve microbe-eliminating concentrations 
is a key requirement for effective antimicrobial treatment. It should be noted that micafungin concentration at 
the site of infection may be above MICs for micafungin susceptible Candida species but below mutant prevention 
concentrations33. This caution is important because intra-abdominal candidiasis is a hidden reservoir for emer-
gence of echinocandin resistance particularly in cases of Candida glabrata infection34. A limitation of the current 
study is that we were unable to evaluate effects of PF on drug penetration into the peritonea and peritoneal cavity.
Figure 3. Histopathological examination of the peritoneum, liver and spleen with H & E and Grocott staining. 
Histopathological examination was performed 12 h after the infection. (A,B) Abscess formation with Candida 
cells in the thickened submesothelial zone of peritoneum was observed with Grocott staining only in the PF 
mice without micafungin treatment. (C) Numerous inflammatory cells were also observed with H & E staining 
in the same sections. (D) Candida proliferation was not detectable in the PF mice with micafungin treatment 
with Grocott staining. Proliferative Candida infiltration into the subcapsular structure inside the liver (E,F) 
and spleen (H,I) were observed with Grocott staining only in the PF mice without micafungin treatment. (G,J) 
Numerous inflammatory cells were also observed with H & E staining in the same sections. The photographs 
are representative of two independent examinations. Magnification, A × 40, B × 400, C × 400, D × 400, E × 100, 
F × 400, G × 400, H × 100, I × 400, and J × 400.
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Concerning the good efficacy of micafungin demonstrated in this study, the regulation of cytokines might also 
be playing an important role. During acute inflammation induced by infection in the peritoneal cavity, proinflam-
matory cytokines are activated during the early period, and the neutrophils recruited are subsequently replaced 
by monocytes35. While proinflammatory and anti-inflammatory cytokines are critical to the elimination of the 
infection, excessive production can cause tissue and organ damages36. It was reported that micafungin suppresses 
LPS-induced TNF-α production and may have immunomodulative effects37. In the present study, we could not 
confirm the suppression of plasma TNF-α concentration by micafungin administration in LPS-exposed mouse 
models, in both PF and control groups. Therefore, the tendency for the suppression of excessive inflammatory 
cytokines in Candida peritonitis mice by micafungin is considered to be due mainly to the secondary effect 
of its direct fungicidal activity against Candida, resulting in an improved survival rate. We considered that 
anti-inflammatory cytokine IL-10 was induced secondarily to inflammatory cytokine production and reduced at 
12 h as a result of the suppression of inflammatory cytokines by micafungin treatment.
In conclusion, the present study demonstrated that Candida peritonitis itself showed a high mortality even in 
subjects without PF, and PF enhanced early mortality in Candida peritonitis. Micafungin showed a good efficacy 
Figure 4. Evaluation of the cytokines in the plasma. (A) The plasma cytokine concentrations of IFN-γ, IL-10, 
IL-17A, IL-1β, IL-6, and TNF-α were quantified by enzyme-linked immunosorbent assay in the following 
groups: control group (control) and PF group (PF) just before infection (0 h); and infected with or without 
micafungin administration, in both PF and control groups at 12 h after the infection (four mice each). All the 
six cytokines at 12 h after the intraperitoneal inoculation of C. albicans tended to be suppressed with micafungin 
treatment in both PF and control groups. (B) The plasma TNF-α concentrations of LPS-exposed mice instead 
of C. albicans inoculation were quantified by enzyme-linked immunosorbent assay, and no significant difference 
was observed between micafungin-treated and -untreated mice in both control and PF groups. Similar results 
were obtained in two different experiments and representative data are shown. Asterisks indicate p < 0.05 
(Mann-Whitney U test). IFN-γ, interferon-gamma; IL-10, interleukin-10; IL-17A, interleukin-17A; IL-1β, 
interleukin-1 beta; IL-6, interleukin-6; TNF-α, tumor necrosis factor alpha; PF, peritoneal fibrosis; and LPS, 
lipopolysaccharide.
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for Candida peritonitis even in the context of PF. This result may also apply to patients who develop PF due to 
intra-abdominal inflammation caused by other reasons besides PD, such as abdominal surgery, intra-abdominal 
infection, and malignant diseases25–27. Considering the high mortality result in the PF groups during the early 
period, early initiation of micafungin is considered important. The Candida peritonitis mouse model with under-
lying PF developed in the present study could also be useful in future studies to evaluate the pathogenicity of 
other Candida strains and the efficacies of other antifungal agents in similar conditions.
Materials and Methods
Ethics. Our animal experiment protocol was pertinently reviewed and approved by the Institutional Animal 
Care and Use Committee of Nagasaki University (approval number 1407281164). All animal experiments were 
performed at the Nagasaki University Laboratory Animal Center for Biomedical Research in accordance with 
the Guide for the Care and Use of Laboratory Animals (National Research Council, National Academy Press, 
Washington DC, 2011) and the institutional regulations and guidelines for animal experimentation.
Murine model of PF. The animals used in this study were specific-pathogen-free male ICR mice (10 weeks of 
age, weighing approximately 40 g; CLEA Japan, Inc., Japan). They were housed in the Biomedical Research Center, 
Life Science Support Center, Nagasaki University.
We induced PF by intraperitoneal administration of CG as described previously4,30–32. Mice received injections 
of 0.1% CG in 15% ethanol, or 15% ethanol alone, at a dose of 0.2 mL/mouse into the peritoneal cavity on alter-
nate days for 3 weeks, 9 times overall.
Evaluation of the peritoneum thickness. For the evaluation of PF, the PF and control mice were sacri-
ficed 4 days after the last CG injection (n = 6 for each group). In order to prevent bias, peritoneal membrane was 
dissected in four locations (upper right, lower right, upper left, and lower left), and evaluated with Masson’s tri-
chrome staining. Thus, four sections were analyzed for each mouse. The thickness of the submesothelial compact 
zone for each section was measured at 10 positions and compared between the PF and control groups, using the 
unpaired t test.
Murine Candida peritonitis and antifungal treatment. Candida peritonitis was induced by 
intraperitoneal inoculation of the C. albicans wild-type strain SC5314. C. albicans cells grown in yeast 
extract-peptone-dextrose (YPD) broth overnight were washed and resuspended in sterile saline and adjusted to 
5.0 × 107 CFU/mL. Mice were infected intraperitoneally with 1000 µL of the Candida suspension 4 days after the 
last CG injection. Non-infected groups were intraperitoneally injected with 1000 µL of sterile saline instead of C. 
albicans cell suspension.
All the mice in the treatment groups were treated with 5 mg/kg of micafungin (500 µg/mL) (Astellas Pharma 
Inc., Tokyo, Japan) injection subcutaneously in the neck, once a day for seven days, beginning 2 h after the intra-
peritoneal injection of C. albicans cell suspension; based on the same administration schedule against candidiasis 
reported previously38.
The MIC of micafungin was ≤0.015 mg/L, determined by dry plate antifungal susceptibility testing of yeasts; 
Eiken (Eiken Chemical Co., Ltd., Tokyo, Japan). We used the subcutaneous route of administration because 
repeated injection into the tail vein of mice is difficult and it is reported that there is only a marginal difference in 
the efficacy of this drug between subcutaneous and intravenous administrations38. The dosage of 5 mg/kg corre-
sponds to 125 mg/day in humans39 consistent with serum concentration-time curve data from 0 to 24 h (AUC0-24) 
between humans and mice40,41. The mice in the non-treatment groups were administered with sterile saline alone 
during the same period.
Evaluation of survival, fungal organ and bloodstream burdens and histopathological examination 
in mice. The survival of the mice was recorded daily after the intraperitoneal injection of C. albicans until day 
20 (n = 8 for each group). Statistical analysis was performed using the Kaplan-Meier method.
To assess the viable cell count of Candida in the organs; the liver, spleen, and bilateral kidneys were excised 
and placed in sterile 0.9% saline at 4 °C immediately after sacrifice, at 6 h, 12 h, and 7 days after the intraperitoneal 
injection of C. albicans (n = 10 for each group). The homogenate was then serially diluted 1:10, and aliquots were 
plated on YPD agar. Blood samples were also collected by cardiac puncture and plated on YPD agar without dilu-
tion. Viable fungal colony counts were determined after 24–48 h incubation at 30 °C. The lower limit of detection 
was 10 CFU/organ. The results were expressed as log10 CFU/organ for the three organs and CFU/mL for blood, 
and analyzed with the Mann-Whitney U test followed by Bonferroni correction.
For the histopathological evaluation, the peritoneum, liver, spleen, and kidney, obtained 12 h after the intra-
peritoneal injection of C. albicans were stained with H & E and Grocott.
Evaluation of the cytokines in the murine blood. The plasma cytokine concentrations of 
interferon-gamma, interleukin-10, interleukin-17A, interleukin-1 beta, interleukin-6, and TNF-α were quanti-
fied using a Bio-Plex ProTM Mouse Cytokine Th17 Panel A 6-Plex (#m6000007ny, Bio-Rad Laboratories, Hercules, 
CA) for the following groups. These were, the control and PF groups just before infection; and infected with or 
without micafungin administration, in both PF and control groups at 12 h after the infection (four mice each).
The plasma TNF-α concentrations in mice exposed to LPS were also quantified as follows: 20 mg/kg of LPS 
were administered intraperitoneally, after 2 h, 5 mg/kg of micafungin (500 µg/mL) was injected subcutaneously 
to the treatment group. Sterile saline was subcutaneously injected to the non-treatment groups. Plasma TNF-α 
concentrations, obtained 6 and 12 h after LPS administration were measured using Mouse TNF alpha Uncoated 
ELISA (88-7324, Thermo Fisher Scientific Inc., Waltham, MA). Each of the groups consisted of four mice.
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Statistical analysis. The unpaired t test was used to assess differences of the PF thickness. The differences of 
fungal burden in the target organs and the cytokines in the plasma were evaluated by using the Mann-Whitney 
U test. Multiple comparisons were adjusted with the Bonferroni method. For all statistical analyses, a value of 
p < 0.05 was considered significant. All statistical analyses were performed using Prism 5.0 (GraphPad Software, 
Inc., La Jolla, CA).
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